IPIX Stock Overview
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective.
Innovation Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.033|
|52 Week High||US$0.54|
|52 Week Low||US$0.019|
|1 Month Change||-17.33%|
|3 Month Change||4.70%|
|1 Year Change||-84.39%|
|3 Year Change||-69.44%|
|5 Year Change||-95.24%|
|Change since IPO||-72.17%|
Recent News & Updates
|IPIX||US Biotechs||US Market|
Return vs Industry: IPIX underperformed the US Biotechs industry which returned -25.6% over the past year.
Return vs Market: IPIX underperformed the US Market which returned -23.2% over the past year.
|IPIX Average Weekly Movement||14.4%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: IPIX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: IPIX's weekly volatility has decreased from 19% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company is also developing Kevetrin, an anti-cancer compound for treating ovarian cancer.
Innovation Pharmaceuticals Fundamentals Summary
|IPIX fundamental statistics|
Is IPIX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IPIX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.014|
|Net Profit Margin||-39,116.67%|
How did IPIX perform over the long term?See historical performance and comparison
Is IPIX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IPIX?
Other financial metrics that can be useful for relative valuation.
|What is IPIX's n/a Ratio?|
Price to Book Ratio vs Peers
How does IPIX's PB Ratio compare to its peers?
|IPIX PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
ONVO Organovo Holdings
EDSA Edesa Biotech
IPIX Innovation Pharmaceuticals
Price-To-Book vs Peers: IPIX is expensive based on its Price-To-Book Ratio (3.6x) compared to the peer average (1.7x).
Price to Earnings Ratio vs Industry
How does IPIX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: IPIX is expensive based on its Price-To-Book Ratio (3.6x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is IPIX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||3.6x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate IPIX's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of IPIX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IPIX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IPIX's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Innovation Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Innovation Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of IPIX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Innovation Pharmaceuticals's filings and announcements here.
How has Innovation Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IPIX is currently unprofitable.
Growing Profit Margin: IPIX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IPIX is unprofitable, but has reduced losses over the past 5 years at a rate of 13.4% per year.
Accelerating Growth: Unable to compare IPIX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IPIX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: IPIX has a negative Return on Equity (-148.86%), as it is currently unprofitable.
Discover strong past performing companies
How is Innovation Pharmaceuticals's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IPIX's short term assets ($4.0M) do not cover its short term liabilities ($4.8M).
Long Term Liabilities: IPIX's short term assets ($4.0M) exceed its long term liabilities ($841.0K).
Debt to Equity History and Analysis
Debt Level: IPIX has more cash than its total debt.
Reducing Debt: IPIX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IPIX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IPIX has less than a year of cash runway if free cash flow continues to grow at historical rates of 10.5% each year.
Discover healthy companies
What is Innovation Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Innovation Pharmaceuticals Dividend Yield vs Market|
|Company (Innovation Pharmaceuticals)||n/a|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (Innovation Pharmaceuticals)||n/a|
Notable Dividend: Unable to evaluate IPIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IPIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IPIX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IPIX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IPIX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Leo Ehrlich (64 yo)
Mr. Leo Ehrlich, CPA serves as Chairman at Innovation Pharmaceuticals Inc. He has been the Chief Executive Officer and Chief Financial Officer of Innovation Pharmaceuticals Inc. (previously known as Cellce...
CEO Compensation Analysis
|Leo Ehrlich's Compensation vs Innovation Pharmaceuticals Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||US$516k||US$466k|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||US$545k||US$466k|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||n/a||n/a|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||US$466k||US$466k|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||n/a||n/a|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||US$466k||US$466k|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||n/a||n/a|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||US$466k||US$466k|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||n/a||n/a|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||US$466k||US$466k|
Compensation vs Market: Leo's total compensation ($USD515.85K) is below average for companies of similar size in the US market ($USD774.31K).
Compensation vs Earnings: Leo's compensation has been consistent with company performance over the past year.
Experienced Management: IPIX's management team is seasoned and experienced (7.1 years average tenure).
Experienced Board: IPIX's board of directors are considered experienced (7.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.3%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Innovation Pharmaceuticals Inc.'s employee growth, exchange listings and data sources
- Name: Innovation Pharmaceuticals Inc.
- Ticker: IPIX
- Exchange: OTCPK
- Founded: 2005
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$16.829m
- Shares outstanding: 503.87m
- Website: https://www.ipharminc.com
Number of Employees
- Innovation Pharmaceuticals Inc.
- 301 Edgewater Place
- Suite 100
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IPIX||OTCPK (Pink Sheets LLC)||Yes||Class A Common Stock||US||USD||Apr 2007|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/01 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.